---
title: "Cagrilintide Dosage Guide [2026] | BodyHackGuide"
url: https://www.bodyhackguide.co/guides/dosage/cagrilintide
description: "Complete Cagrilintide dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026."
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

Metabolic & Weight Loss Phase 3

# Cagrilintide Dosage Guide: Protocols, Calculator & Safety

Everything you need to know about Cagrilintide dosing: protocols, safety, and where to buy.

Frequency

Once weekly

Half-Life

~159 hours (approximately 7 days)

Dosage Calculator

Calculate exact dosing for Cagrilintide.
https://www.bodyhackguide.co/tools/dosage

## Dosing Protocols

Beginner

**Context:** CagriSema is not yet FDA-approved (as of April 2026 — Phase 3 REDEFINE program complete, approval expected 2025-2026). This beginner protocol assumes either clinical trial enrollment, off-label compounded cagrilintide + semaglutide use, or early commercial availability.

**Preparation Phase (Weeks -2 to 0):**

- Confirm BMI ≥27 (with comorbidities) or ≥30 for obesity indication
- Baseline labs: HbA1c, lipid panel, liver enzymes, TSH, testosterone (men), basic metabolic panel
- Body composition baseline: DEXA scan (preferred) or impedance analysis
- Medical history review: pancreatitis history, thyroid disease (MTC/MEN2 contraindicated), family history of thyroid cancer
- Mental health screening: eating disorder history, depression
- Weight history documentation
- Discuss realistic expectations (20-22% weight loss at 68 weeks is the high end)

**Beginner Protocol (Weeks 1-16):**

**CagriSema Initiation:**

- Week 1-4: Semaglutide 0.25 mg SC weekly + Cagrilintide 0.3 mg SC weekly
- Week 5-8: Semaglutide 0.5 mg SC weekly + Cagrilintide 0.6 mg SC weekly
- Week 9-12: Semaglutide 1.0 mg SC weekly + Cagrilintide 1.2 mg SC weekly
- Week 13-16: Semaglutide 1.7 mg SC weekly + Cagrilintide 2.4 mg SC weekly
- Week 17+: Semaglutide 2.4 mg + Cagrilintide 2.4 mg (full dose)

**Injection Timing:**

- Same day each week (typically Sunday or Monday)
- Two separate injections (semaglutide and cagrilintide) — cannot be pre-mixed in same syringe
- Can be same injection site area or different
- Rotate sites to prevent irritation

**Administration:**

- Subcutaneous injection
- Abdomen, thigh, or upper arm
- 29-31G insulin syringes (5/16" or 1/2")
- Clean site, inject slowly, brief pressure after
- Dispose needle in sharps container

**Dietary Guidance:**

- Eat smaller portions — appetite will be significantly reduced
- Prioritize protein: 1.6-2.0 g/kg ideal body weight to preserve lean mass
- Adequate hydration: 2-3 L water daily
- Moderate carbohydrate intake
- Avoid late-night eating (gastric emptying already slowed)
- Multivitamin supplementation

**Exercise Guidance:**

- **Resistance training 2-3x weekly**: preserve lean muscle mass during rapid weight loss
- Compound movements: squats, deadlifts, presses, pulls
- Progressive overload approach
- Adequate recovery (weight loss is a stressor)
- Cardiovascular: 150 min/week moderate OR 75 min/week vigorous

**Weeks 1-4 Expectations:**

- Initial GI side effects likely: nausea, appetite suppression, early satiety
- Weight loss: typically 2-4% of body weight
- Fatigue, especially with rapid weight loss
- Mild dehydration risk

**Weeks 5-12 Expectations:**

- GI tolerance improves
- Weight loss continues: typically 4-8% by week 12
- Energy typically normalizes
- Ongoing titration requires patience

**Week 16 Decision Points:**

- If full dose tolerated and weight loss on track: continue to intermediate protocol
- If ongoing GI symptoms limiting dose: maintain current dose longer before escalating
- If plateau: reassess calorie intake, exercise, adherence
- If intolerable side effects: reduce dose or switch therapy

**Monitoring:**

- Weekly: body weight, blood pressure, subjective symptoms
- Month 1: clinical check-in, adjust titration as needed
- Month 3: comprehensive labs + body composition
- Month 6: comprehensive labs + body composition + DEXA

**Red Flags Requiring Medical Attention:**

- Severe persistent nausea/vomiting with dehydration
- Severe abdominal pain (pancreatitis concern)
- Symptoms suggestive of gallbladder disease
- Severe fatigue beyond expected
- Mood changes or depression
- Any signs of hypoglycemia (especially if diabetic)
- Neck mass or thyroid-related symptoms

**What Beginner Protocol Does NOT Cover:**

- Maintenance dosing after initial 6-12 month weight loss phase
- Management of weight regain after discontinuation
- Pediatric use
- Pregnancy (contraindicated)
- Complex diabetic management (requires endocrinology co-management)

Standard

**For users who have completed 16+ weeks of titration successfully and want to optimize long-term weight loss maintenance.**

**Intermediate Protocol (Months 4-12):**

**Full Maintenance Dose:**

- Semaglutide 2.4 mg SC weekly
- Cagrilintide 2.4 mg SC weekly
- Consistent weekly schedule
- Most weight loss occurs in this phase

**Optimization Strategies:**

**Protein Optimization:**

- 1.6-2.0 g/kg ideal body weight daily
- Distribute across 3-4 meals (20-40 g per meal)
- Leucine-rich sources preferred (dairy, meat, whey)
- Consider whey protein supplementation if intake falls short

**Resistance Training Progression:**

- Progressive overload essential
- 3-4 sessions weekly during stable dosing phase
- Compound movements prioritized
- Track strength metrics (not just weight)
- Consider personal trainer or structured program

**Cardiovascular Exercise:**

- 150 minutes moderate-intensity OR 75 minutes vigorous weekly
- HIIT 1-2x weekly for metabolic benefits
- Walking for active recovery
- Avoid overtraining (rest is part of program)

**Nutritional Quality:**

- Whole food emphasis
- Adequate fiber (25-35 g daily)
- Fatty fish 2x weekly for omega-3
- Abundant vegetables for micronutrients
- Limit ultra-processed foods

**Sleep Optimization:**

- 7-9 hours nightly
- Consistent sleep/wake schedule
- Appropriate sleep environment
- Address sleep apnea if present (weight loss may improve)

**Stress Management:**

- Chronic stress impairs weight loss
- Meditation, mindfulness, or therapy as appropriate
- Social support for eating behavior changes
- Address underlying emotional eating

**Hormonal Monitoring:**

**Thyroid:**

- TSH, free T4 every 6 months
- Weight loss may alter thyroid needs
- Adjust replacement as needed

**HPG Axis:**

- Men: testosterone every 6 months during rapid weight loss
- Women: menstrual tracking; if amenorrhea develops, consult reproductive endocrinology
- Significant weight loss can suppress HPG axis via leptin reduction

**Metabolic Markers:**

- HbA1c every 3-6 months
- Lipid panel every 3-6 months
- Liver enzymes quarterly initially
- Kidney function annually

**Body Composition:**

- DEXA every 6 months (gold standard)
- Track lean mass, fat mass, visceral adipose tissue
- Target: preserve or minimize lean mass loss during weight loss
- Redistribute if lean mass dropping excessively (increase protein, resistance training)

**Common Intermediate Phase Issues:**

**Plateau (months 6-9):**

- Expected for most patients around 40-50% of total expected weight loss
- Reassess caloric intake (may need adjustment)
- Reassess activity levels
- Check adherence to injections
- Consider adding resistance training if not already

**Decreased Appetite Extremes:**

- If inadequate caloric intake threatens lean mass: prioritize protein
- Structured meal timing despite low hunger
- Consider temporary dose reduction if severe

**Lean Mass Loss:**

- Monitor via DEXA
- Intervene: increase protein, intensify resistance training
- Consider GH peptides (Sermorelin (https://www.bodyhackguide.co/compound/sermorelin), CJC-1295 (https://www.bodyhackguide.co/compound/cjc-1295)/Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin)) if significant
- Slow rate of weight loss if needed

**Expected Trajectory:**

- Month 6: 10-15% weight loss typical
- Month 9: 15-20% weight loss typical
- Month 12: 18-22% weight loss typical (matches REDEFINE 1 landmark cohort)
- Month 18: plateau approaches typical nadir

**Side Effect Management:**

**Persistent GI Issues:**

- Usually improve with time
- Split injection or timing changes don't affect weekly drugs
- Ondansetron for persistent nausea (physician guidance)
- Eat smaller, more frequent meals

**Fatigue:**

- Ensure adequate calories (not excessive deficit)
- Adequate sleep
- Iron studies if persistent
- Thyroid status check

**Hair Loss:**

- Common during rapid weight loss
- Usually resolves when weight stabilizes
- Adequate protein, zinc, biotin
- Genetics a factor

**Quality of Life Monitoring:**

- Energy levels
- Mood and mental health
- Social eating situations
- Body image (positive and negative)
- Sleep quality
- Sexual function

**Partner/Family Support:**

- Education on weight-loss drugs
- Eating pattern changes
- Support for new lifestyle
- Joint meal planning

**When to Consider Transition:**

**Progress to Advanced Protocol:**

- After 12-18 months of successful weight loss
- Stable lifestyle habits established
- Addressing long-term maintenance

**Modify Approach:**

- If progress stalls >3 months
- If side effects become intolerable
- If complex medical issues develop

**Reduce Dose:**

- After reaching target weight
- If lean mass loss excessive
- Part of maintenance planning

**Discontinue:**

- Target weight achieved with stable lifestyle
- Medical necessity
- Insurance coverage issues
- Personal choice
- Always with maintenance plan to prevent regain

Advanced

**For experienced users approaching or maintaining target weight, typically 12-24+ months into therapy.**

**Advanced Use Case 1: Maintenance After Weight Loss Goal Achievement**

**Scenario:** Target weight reached, transitioning to long-term maintenance.

**Protocol Options:**

**Option A: Continued Full Dose Maintenance**

- Continue CagriSema 2.4 mg + 2.4 mg weekly
- Rationale: strongest evidence for preventing regain
- Drawback: ongoing cost and side effects

**Option B: Reduced Maintenance Dose**

- CagriSema 1.2 mg + 1.2 mg weekly (half dose)
- Some clinical evidence for maintenance at lower doses
- Balance: cost, convenience, prevention of regain

**Option C: Semaglutide Alone Maintenance**

- Discontinue cagrilintide, continue semaglutide 2.4 mg weekly
- Rationale: leverage established GLP-1 monotherapy maintenance data
- Concern: may see some regain vs dual therapy

**Option D: Gradual Discontinuation**

- Taper both drugs over 6-12 months
- Intensive lifestyle reinforcement
- Expect some regain (average ~50% of lost weight over 1-2 years post-discontinuation based on other weight-loss drug data)

**Advanced Use Case 2: Weight Regain After Discontinuation**

**Scenario:** Patient discontinued CagriSema, now regaining.

**Protocol:**

- Reassess readiness and realistic goals
- Re-initiate CagriSema with titration (may be faster titration given prior exposure)
- Lifestyle intervention intensification
- Consider behavioral therapy
- Address underlying factors (stress, sleep, medications)

**Advanced Use Case 3: Aggressive Weight Loss + Body Recomposition**

**Scenario:** Beyond standard weight loss — targeting specific body composition.

**Protocol:**

- CagriSema 2.4 mg + 2.4 mg weekly
- Intensive resistance training (4-5x weekly)
- Protein 2.0+ g/kg ideal body weight
- Monitoring: DEXA every 3 months
- Optional: GH peptides (Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin) for visceral fat, CJC-1295 (https://www.bodyhackguide.co/compound/cjc-1295)/Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin) for lean mass support)
- HPG axis monitoring and support if needed
- Medical oversight recommended

**Advanced Use Case 4: Diabetic Patient Optimization**

**Scenario:** Type 2 diabetes with obesity, seeking glycemic and weight control.

**Protocol:**

- CagriSema 2.4 mg + 2.4 mg weekly
- Monitor HbA1c monthly during initiation
- Reduce insulin/sulfonylurea doses proactively (hypoglycemia risk)
- Coordinate with endocrinology
- May be able to discontinue some diabetes medications
- Target: HbA1c <7.0% and meaningful weight loss

**Advanced Use Case 5: Post-Bariatric Surgery Patient**

**Scenario:** Post-bariatric regain or inadequate response.

**Protocol:**

- CagriSema 2.4 mg + 2.4 mg weekly
- Careful monitoring for GI effects (altered anatomy)
- Adjust based on tolerance
- Multivitamin/mineral supplementation (bariatric-appropriate)
- Medical oversight essential
- May need lower doses than non-bariatric patients

**Complex Monitoring for Advanced Protocols:**

- Quarterly comprehensive labs
- DEXA every 3-6 months
- Thyroid panel every 6 months
- HPG axis every 6 months
- Cardiovascular assessment annually
- Mental health screening ongoing
- Quality of life measures

**Integration with Multi-Peptide Protocols:**

**With GH Axis:**

- Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin) for visceral fat reduction (evidence-based in HIV lipodystrophy)
- Sermorelin (https://www.bodyhackguide.co/compound/sermorelin) or CJC-1295 (https://www.bodyhackguide.co/compound/cjc-1295)/Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin) for lean mass preservation
- Timing: GH peptides evening, CagriSema any weekly time

**With Reproductive Axis:**

- Gonadorelin (https://www.bodyhackguide.co/compound/gonadorelin) or HCG (https://www.bodyhackguide.co/compound/hcg) for men with rapid testosterone decline
- Enclomiphene (https://www.bodyhackguide.co/compound/enclomiphene) for long-term HPG maintenance
- Reproductive endocrinology for women with amenorrhea

**With Repair/Recovery:**

- BPC-157 (https://www.bodyhackguide.co/compound/bpc-157), TB-500 (https://www.bodyhackguide.co/compound/tb-500) for joint/tissue during increased activity
- Thymosin-beta-4 family peptides
- Timing: independent of CagriSema

**Long-Term Safety Surveillance:**

- Annual thyroid ultrasound if concerning history
- Lifetime monitoring for pancreatitis signs
- Gallbladder assessment if symptoms
- Mental health vigilance
- Cancer screening age-appropriate

**When to Consult Specialist:**

- Endocrinology: complex diabetes, thyroid abnormalities
- Bariatric medicine: post-surgery or resistant cases
- Cardiology: cardiovascular disease
- Psychiatry: mental health concerns
- Reproductive endocrinology: fertility issues
- Oncology: concerning signs or findings

**Quality of Life Optimization:**

- Social eating strategies
- Travel planning (refrigeration, time zones)
- Stress management long-term
- Partner/family involvement
- Professional support (therapist, dietitian, trainer)

## Commonly Stacked With

Cagrilintide is uniquely positioned as part of a designed combination (CagriSema) rather than a monotherapy, making stacking considerations substantially different from other peptides.

**Primary Stack: CagriSema (Cagrilintide + Semaglutide)** This is the intended combination therapy:

- Semaglutide (https://www.bodyhackguide.co/compound/semaglutide) 2.4 mg SC weekly
- Cagrilintide 2.4 mg SC weekly (same injection day, can be same or different site)
- Combined weight loss: 20-22% at 68 weeks
- Mechanism: dual-axis anorexia (GLP-1 + amylin) without proportional GI increase

**Cagrilintide Monotherapy:**

- Possible at 4.5 mg weekly (Phase 2-established dose)
- Weight loss: 10-11% at 26 weeks
- Less common than CagriSema positioning; most commercial path emphasizes combination
- Potentially useful in patients unable to tolerate GLP-1 agonists

**With Tirzepatide (Theoretical):**

- Hypothetical GLP-1/GIP + amylin combination
- No clinical evidence; not commercially developed
- Risk: unpredictable combined GI burden
- Not recommended without clinical trial data

**With Retatrutide (Theoretical):**

- GLP-1/GIP/glucagon + amylin would be quadruple mechanism
- Pre-clinical rationale possible
- No human data
- Likely too aggressive for initial development

**Lifestyle + CagriSema:** The most evidence-based stack — CagriSema combined with:

- Structured resistance training (preserves lean mass during weight loss)
- Adequate protein intake (1.6-2.0 g/kg ideal body weight)
- Caloric deficit nutritionally balanced
- Monitoring body composition (DEXA) rather than just scale weight
- Psychological support for eating behavior changes

**With Other Peptides:**

**Growth Hormone Peptides for Lean Mass Preservation:**

- Sermorelin: https://www.bodyhackguide.co/compound/sermorelin
  ,
  CJC-1295: https://www.bodyhackguide.co/compound/cjc-1295
   \+
  Ipamorelin: https://www.bodyhackguide.co/compound/ipamorelin
  ,
  Tesamorelin: https://www.bodyhackguide.co/compound/tesamorelin
- Rationale: preserve lean mass during aggressive weight loss
- Evidence: limited direct combination data
- Consideration: timing (GH peptides in evening; cagrilintide any time weekly)

**Thyroid Support:**

- Not routinely indicated
- Some rapid weight loss causes mild T3/T4 changes
- Monitor TSH/free T4 every 3-6 months during aggressive weight loss
- Adjust existing thyroid replacement if needed

**HPG Axis Preservation:**

- Rapid weight loss can suppress testosterone in men and menstrual cyclicity in women
- Gonadorelin (https://www.bodyhackguide.co/compound/gonadorelin) or Enclomiphene (https://www.bodyhackguide.co/compound/enclomiphene) for men losing testosterone
- Reproductive endocrinology consultation for women with amenorrhea

**Repair Peptides:**

- BPC-157: https://www.bodyhackguide.co/compound/bpc-157
  ,
  TB-500: https://www.bodyhackguide.co/compound/tb-500
- No direct interaction with cagrilintide mechanism
- May support joint/tissue health during weight loss and increased activity
- Timing independent

**Immune Support:**

- Thymosin-Alpha-1: https://www.bodyhackguide.co/compound/thymosin-alpha-1
  ,
  LL-37: https://www.bodyhackguide.co/compound/ll-37
- No known interaction
- Consider if recurrent infections during weight loss

**Avoid These Combinations:**

- **Cagrilintide + pramlintide**: same receptor target; redundant and potentially excessive
- **High-dose sulfonylureas or insulin without dose reduction**: hypoglycemia risk (especially in diabetic patients)
- **Other weight-loss drugs without physician oversight**: bupropion, phentermine, topiramate may produce unpredictable combined effects
- **Undisclosed research-grade supplementation without physician awareness**

**Sequencing Strategies:**

- **Ramp-up**: start cagrilintide 0.3 mg weekly, titrate over 12-16 weeks to 2.4 mg
- **If on semaglutide**: add cagrilintide 0.3 mg weekly, titrate as tolerated
- **If tirzepatide naive**: CagriSema is the evidence-based combination; adding amylin to tirzepatide has no clinical data
- **Plateau management**: if weight loss plateaus on semaglutide alone, adding cagrilintide (CagriSema) is evidence-based

**Monitoring Stack:**

- Weight: weekly during titration, monthly maintenance
- Body composition: DEXA or impedance baseline and every 3-6 months
- Lipid panel, HbA1c, liver enzymes baseline and every 3-6 months
- Thyroid function baseline and annually
- HPG axis (testosterone, menstrual cyclicity) as relevant

**Discontinuation Planning:** Weight regain after discontinuation is well-documented for all weight-loss drugs. Strategies to minimize regain:

- Gradual dose reduction rather than abrupt stop
- Aggressive lifestyle reinforcement in final months
- Maintenance lower-dose consideration (emerging practice)
- Body composition monitoring to detect lean mass loss
- Psychological support for behavioral maintenance

## Side Effects & Safety

Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. **Most Common Side Effects (from trials):** **Gastrointestinal (dose-dependent):** - **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing - **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss - **Diarrhea**: moderate frequency - **Constipation**: less common than with semaglutide - **Decreased appetite**: expected and desired effect; can become problematic if excessive - **Dyspepsia / abdominal discomfort**: moderate frequency - **Early satiety**: expected effect, sometimes extreme **Metabolic Effects:** - **Fatigue**: modest, especially during rapid weight loss - **Headache**: mild-to-moderate, transient - **Dizziness**: especially in dehydrated individuals or with rapid dose escalation - **Injection site reactions**: mild, transient **CagriSema-Specific Considerations:** When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. **Rare Serious Adverse Events:** - **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required - **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug) - **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients **Amylin-Specific Considerations:** **Amyloidogenicity Concerns:** Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. **Calcitonin Receptor Effects:** Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: - Thyroid C-cell effects (as with GLP-1 agonists) - Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. **Thyroid C-Cell Tumors:** Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. **Specific Populations:** **Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. **Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. **Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. **Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction. **Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval. **Red Flags Requiring Discontinuation:** - Severe persistent nausea/vomiting unresponsive to supportive care - Signs of pancreatitis (severe abdominal pain radiating to back) - Signs of gallbladder disease (RUQ pain, jaundice) - Signs of hypoglycemia requiring rescue (especially in diabetic patients) - Psychiatric symptoms: significant mood changes - Severe injection site reactions - Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) **Long-Term Safety:** As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: - Cancer signals (particularly thyroid) - Cardiovascular outcomes - Psychiatric effects - Weight regain trajectory after discontinuation - Effects on lean muscle mass **Comparison with Other Weight-Loss Drugs:** Cagrilintide (and by extension CagriSema) appears to have: - Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) - Better than liraglutide for convenience (once weekly vs daily) - Less long-term data than liraglutide, semaglutide, or tirzepatide

Contraindications

**Absolute Contraindications:** - **Personal or family history of medullary thyroid carcinoma (MTC)** - **Multiple endocrine neoplasia type 2 (MEN2)** - **Known hypersensitivity** to cagrilintide, semaglutide, or any component - **Pregnancy** (weight loss contraindicated) - **Active eating disorder** (anorexia nervosa, severe bulimia) - **Severe untreated psychiatric conditions** **Relative Contraindications (Require Careful Evaluation):** - **History of pancreatitis**: not absolute but high caution - **Severe gastroparesis**: may worsen - **Gallbladder disease**: increased risk during rapid weight loss - **Inflammatory bowel disease**: caution with GI effects - **Severe renal impairment** (eGFR <30): limited data - **Severe hepatic impairment**: limited data - **Age >75**: careful titration needed - **Children/adolescents**: not yet studied **Drug Interactions:** **Medications Requiring Adjustment:** - **Insulin**: may need 20-40% dose reduction (hypoglycemia risk) - **Sulfonylureas**: consider dose reduction or discontinuation - **Thyroid replacement**: monitor and adjust as weight changes - **Levothyroxine**: absorption may be affected; separate by 30 min+ - **Oral contraceptives**: absorption may be altered; barrier backup recommended - **Warfarin**: monitor INR (altered absorption possible) **Medications to Use with Caution:** - **Other GLP-1 agonists**: avoid concurrent use (redundant, increased AE) - **Other amylin analogs** (pramlintide): avoid concurrent use - **Opioids**: may worsen constipation - **Sedatives**: may worsen dizziness - **Lithium**: altered clearance possible **Medications Compatible:** - Most antihypertensives - Statins - Metformin (often beneficial combination) - SSRIs (monitor mood changes) - Most thyroid medications (with monitoring) - Most HRT (estrogen, testosterone) **Medical Conditions Requiring Caution:** **Gastrointestinal:** - Gastroparesis: worsening risk - Inflammatory bowel disease: caution - Peptic ulcer disease: monitor - History of bowel obstruction: contraindicated **Pancreatic:** - History of pancreatitis: high caution - Pancreatic insufficiency: monitor - Pancreatic cancer risk: theoretical **Thyroid:** - Medullary thyroid carcinoma (personal or family): contraindicated - MEN2 syndrome: contraindicated - Benign thyroid nodules: monitor - Autoimmune thyroiditis: manage thyroid function separately **Gallbladder:** - Gallstones: increased risk with rapid weight loss - Previous cholecystectomy: no additional contraindication - Active symptoms: manage before starting **Cardiovascular:** - Recent myocardial infarction: delay start - Severe heart failure: monitor - Hypertension: typically improves with weight loss **Renal:** - Mild-moderate impairment: no major concerns - Severe impairment (eGFR <30): limited data - Hemodialysis: not well-studied **Hepatic:** - Non-alcoholic fatty liver: typically improves with weight loss - Severe cirrhosis: limited data - Alcoholic liver disease: manage separately **Psychiatric:** - Depression: monitor closely (any weight-loss drug can affect mood) - Anxiety disorders: monitor - History of suicidal ideation: careful monitoring - Eating disorders: contraindicated if active **Pregnancy/Reproductive:** - Pregnancy: absolute contraindication - Breastfeeding: not well-studied - Effective contraception during treatment - Pre-conception: discontinue 4-6 weeks before **When to Stop Immediately:** - Anaphylactoid/severe hypersensitivity reaction - Severe persistent pancreatitis symptoms - Suspected medullary thyroid cancer - Severe gallbladder disease - Severe psychiatric emergency - Pregnancy (discovery or planning) - Severe unexplained weight loss **When to Consult Physician:** - Severe or persistent GI symptoms - Suspected pancreatitis - New thyroid symptoms (neck mass, dysphagia) - Gallbladder symptoms - Significant mood changes - Severe fatigue - Unexpected labs - Pregnancy plans - New medical conditions **Pre-Treatment Assessment:** - Complete medical history - Medication reconciliation - Baseline labs (complete metabolic panel, lipids, HbA1c, TSH, liver enzymes) - Mental health screening - Physical exam - ECG if cardiovascular concerns - Pregnancy test if applicable - Patient education on risks/benefits **Monitoring Schedule:** - **Baseline**: complete evaluation - **Month 1**: clinical visit, symptoms review - **Month 3**: labs + clinical assessment - **Month 6**: labs + body composition + complete reassessment - **Month 12**: annual evaluation - **Ongoing**: symptom tracking, quality of life **Integration with Medical Care:** CagriSema/cagrilintide use benefits from clinical oversight: - Primary care with weight management expertise - Endocrinology for complex diabetes or thyroid - Bariatric medicine for advanced cases - Nutrition counseling - Mental health support Solo use is possible but coordination with physicians optimizes outcomes and safety. Insurance coverage often requires specific documentation and monitoring.

Check interactions with the Interaction Checker → (https://www.bodyhackguide.co/tools/interaction-checker)

## Additional Notes

**Standard Dose Ranges:**

**Cagrilintide Monotherapy (Phase 2 established):**

- Initiation: 0.3 mg SC weekly
- Titration: 0.6 1.2 2.4 4.5 mg weekly
- Maintenance: 2.4-4.5 mg weekly
- Increment interval: every 4 weeks

**CagriSema Combination (Phase 3 standard):**

- Semaglutide 2.4 mg + Cagrilintide 2.4 mg SC weekly
- ~16-week co-escalation to full dose
- Maintenance: ongoing weekly dosing

**Dose Escalation Rationale:** The titration protocol is designed to minimize GI side effects. Most nausea and vomiting occurs during dose escalation phases. Slower titration may be warranted in:

- Patients with severe initial GI response
- Elderly patients
- Patients with complex medical conditions

**Dose Reduction Strategies:**

- If intolerable nausea: reduce to previous tolerated dose for 4 more weeks, then re-escalate
- If severe GI issues persist: consider switching to monotherapy (semaglutide or cagrilintide alone)
- If weight loss excessive: reduce maintenance dose
- If lean mass loss concerning: optimize protein/exercise first, then consider dose reduction

**Dose Dependence Relationships:**

**Weight Loss vs Dose (cagrilintide monotherapy - Phase 2, Lau et al. 2021, 26 weeks):**

- Across the full 0.3-4.5 mg dose range, mean weight loss was 6.0%-10.8% vs 3.0% for placebo (the dose-response curve is relatively flat above ~1 mg)
- 4.5 mg (highest dose): 10.8%, exceeding once-daily liraglutide 3.0 mg (9.0%)
- Reference: Lau et al., 2021 (https://pubmed.ncbi.nlm.nih.gov/34798060/)

**Side Effects vs Dose:**

- Higher doses: more nausea, vomiting
- Typically manageable with titration
- Most GI effects diminish with continued dosing

**Timing Considerations:**

**Day of Week:**

- Any day works
- Consistency matters more than specific day
- Sunday or Monday common (align with weekly rhythm)
- Avoid Friday/Saturday (GI effects during social eating)

**Time of Day:**

- Any time works (long half-life smooths effects)
- Morning may be preferable for those with evening social eating
- Consistency matters more than specific time

**Injection Site Rotation:**

- Abdomen (2+ inches from navel)
- Thigh (outer)
- Upper arm (back)
- Rotate sites each injection
- Record to avoid lipohypertrophy

**Source Quality:**

**Pharmaceutical-Grade (Preferred):**

- Once FDA-approved, use commercial product
- Clinical trial supply during trials
- Compounded from licensed pharmacy (current off-label option)
- USP-grade peptide verification

**Research-Grade (Lower Quality):**

- Grey-market sources
- Variable purity
- Storage concerns
- Not recommended for therapeutic use

**Recognizing Quality:**

- Clear labeling
- Expected concentration
- Reputable source
- Third-party COA
- Proper storage during shipping

**Special Considerations:**

**Concurrent Medications:**

- Insulin: may need 20-40% reduction
- Sulfonylureas: consider discontinuation
- Thyroid replacement: may need adjustment
- Oral contraceptives: delayed absorption during rapid gastric emptying change
- All prescriptions: inform physicians

**Pregnancy/Breastfeeding:**

- Not indicated during pregnancy
- Discontinue before planned conception
- Not studied during lactation
- Effective contraception during treatment

**Elderly (>75):**

- Slower titration
- Lower doses may be sufficient
- Monitor for falls with weight loss
- Assess cognitive status

**Pediatric:**

- Not yet studied
- Pediatric trials may follow adult approval
- Childhood obesity is increasing
- Specific pediatric considerations will apply

**Renal Impairment:**

- Not primarily renally cleared
- Monitor in severe renal disease
- Adjust based on response and tolerance

**Hepatic Impairment:**

- Limited data
- Caution in severe hepatic dysfunction
- Monitor liver enzymes

**Surgical Considerations:**

- GLP-1 agonist component associated with retained gastric contents
- Discontinue before surgery per anesthesia guidance
- Coordinate with surgical team
- Resume after recovery

**Cost Considerations:**

- Expected to be expensive (similar to other GLP-1 combination therapies)
- Insurance coverage variable
- Manufacturer programs may be available
- Cost-benefit analysis for individual patients
- Long-term investment in health

**Storage:**

- Refrigerate (2-8 deg C)
- Do not freeze
- Light protection preferred
- Follow specific product instructions at approval

Where to Buy Cagrilintide

Compare 4 listings across 4 vendors, from $49.99
https://www.bodyhackguide.co/compound/cagrilintide

## Frequently Asked Questions

What is the recommended Cagrilintide dosage?

Dosage for Cagrilintide varies by protocol. Consult a qualified healthcare provider.

How often should I take Cagrilintide?

Once weekly

Does Cagrilintide need to be cycled?

Cycling requirements depend on the protocol. Follow established research guidelines.

What are Cagrilintide side effects?

Where can I buy Cagrilintide?

Compare 4 listings from 4 vendors on our price comparison page, starting from $49.99.

Cagrilintide Full Profile

Research data, mechanisms, and pricing
https://www.bodyhackguide.co/compound/cagrilintide

Interaction Checker

Check drug & compound interactions
https://www.bodyhackguide.co/tools/interaction-checker

## Related Dosage Guides

All Guides (https://www.bodyhackguide.co/guides)

### AOD-9604

Metabolic & Weight Loss · Dosage Guide
https://www.bodyhackguide.co/guides/dosage/aod-9604

### HGH Fragment 176-191

Metabolic & Weight Loss · Dosage Guide
https://www.bodyhackguide.co/guides/dosage/hgh-frag-176-191

### Retatrutide

Metabolic & Weight Loss · Dosage Guide
https://www.bodyhackguide.co/guides/dosage/retatrutide

### Semaglutide

Metabolic & Weight Loss · Dosage Guide
https://www.bodyhackguide.co/guides/dosage/semaglutide

Free 2026 Peptide Cheat Sheet (PDF)

38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download)

Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp)

### BodyHackGuide

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

#### Explore

- Compare prices: https://www.bodyhackguide.co/compare
- Vendors: https://www.bodyhackguide.co/vendors
- Deals: https://www.bodyhackguide.co/deals
- Coupons: https://www.bodyhackguide.co/coupons
- Nootropics: https://www.bodyhackguide.co/nootropics
- Brain health: https://www.bodyhackguide.co/brain-health
- Blog: https://www.bodyhackguide.co/blog
- Guides: https://www.bodyhackguide.co/guides

#### Tools

- Reconstitution: https://www.bodyhackguide.co/tools/reconstitution
- Half-life visualizer: https://www.bodyhackguide.co/tools/halflife
- COA reader: https://www.bodyhackguide.co/tools/coa
- Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator
- Stack builder: https://www.bodyhackguide.co/stack-builder
- All tools: https://www.bodyhackguide.co/tools

#### Trust & vendors

- Vendor directory: https://www.bodyhackguide.co/vendors
- Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard
- Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted
- Scoring methodology: https://www.bodyhackguide.co/vendors/methodology
- Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download

#### Company

- About: https://www.bodyhackguide.co/about
- Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure
- Editorial standards: https://www.bodyhackguide.co/editorial-standards
- Creators: https://www.bodyhackguide.co/creators
- Coaches: https://www.bodyhackguide.co/coaches
- 1-on-1 coaching: https://www.bodyhackguide.co/coaching
- Privacy: https://www.bodyhackguide.co/privacy
- Terms: https://www.bodyhackguide.co/terms
- Full site directory: https://www.bodyhackguide.co/site-directory

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy)

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Cagrilintide Dosage Guide [2026]",
    "description": "Complete Cagrilintide dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026.",
    "author": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "reviewedBy": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "publisher": {
      "@type": "Organization",
      "name": "BodyHackGuide",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/bhglogo.png"
      }
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "FAQPage",
    "mainEntity": [
      {
        "@type": "Question",
        "name": "What is the recommended Cagrilintide dosage?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Dosage for Cagrilintide varies by protocol. Consult a qualified healthcare provider."
        }
      },
      {
        "@type": "Question",
        "name": "How often should I take Cagrilintide?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Once weekly"
        }
      },
      {
        "@type": "Question",
        "name": "Does Cagrilintide need to be cycled?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Cycling requirements depend on the protocol. Follow established research guidelines."
        }
      },
      {
        "@type": "Question",
        "name": "What are Cagrilintide side effects?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations.\n\n**Most Common Side Effects (from trials):**\n\n**Gastrointestinal (dose-dependent):**\n- **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo)  -  generally mild-to-moderate, tends to decrease with continued dosing\n- **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss\n- **Diarrhea**: moderate frequency\n- **Constipation**: less common than with semaglutide\n- **Decreased appetite**: expected and desired effect; can become problematic if excessive\n- **Dyspepsia / abdominal discomfort**: moderate frequency\n- **Early satiety**: expected effect, sometimes extreme\n\n**Metabolic Effects:**\n- **Fatigue**: modest, especially during rapid weight loss\n- **Headache**: mild-to-moderate, transient\n- **Dizziness**: especially in dehydrated individuals or with rapid dose escalation\n- **Injection site reactions**: mild, transient\n\n**CagriSema-Specific Considerations:**\nWhen combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate.\n\n**Rare Serious Adverse Events:**\n- **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required\n- **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug)\n- **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients\n\n**Amylin-Specific Considerations:**\n\n**Amyloidogenicity Concerns:**\nNative amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration.\n\n**Calcitonin Receptor Effects:**\nCagrilintide retains some calcitonin receptor binding, raising theoretical concerns about:\n- Thyroid C-cell effects (as with GLP-1 agonists)\n- Calcium/phosphate homeostasis (calcitonin's native role)\n\nTrials to date have not shown clinically meaningful effects in these domains.\n\n**Thyroid C-Cell Tumors:**\nLike GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide.\n\n**Specific Populations:**\n\n**Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception.\n\n**Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss.\n\n**Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates.\n\n**Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction.\n\n**Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval.\n\n**Red Flags Requiring Discontinuation:**\n- Severe persistent nausea/vomiting unresponsive to supportive care\n- Signs of pancreatitis (severe abdominal pain radiating to back)\n- Signs of gallbladder disease (RUQ pain, jaundice)\n- Signs of hypoglycemia requiring rescue (especially in diabetic patients)\n- Psychiatric symptoms: significant mood changes\n- Severe injection site reactions\n- Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness)\n\n**Long-Term Safety:**\nAs a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for:\n- Cancer signals (particularly thyroid)\n- Cardiovascular outcomes\n- Psychiatric effects\n- Weight regain trajectory after discontinuation\n- Effects on lean muscle mass\n\n**Comparison with Other Weight-Loss Drugs:**\n\nCagrilintide (and by extension CagriSema) appears to have:\n- Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism)\n- Better than liraglutide for convenience (once weekly vs daily)\n- Less long-term data than liraglutide, semaglutide, or tirzepatide"
        }
      },
      {
        "@type": "Question",
        "name": "Where can I buy Cagrilintide?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Compare 4 listings from 4 vendors on our price comparison page, starting from $49.99."
        }
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://www.bodyhackguide.co/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Guides",
        "item": "https://www.bodyhackguide.co/guides"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Dosage Guides",
        "item": "https://www.bodyhackguide.co/guides"
      },
      {
        "@type": "ListItem",
        "position": 4,
        "name": "Cagrilintide Dosage",
        "item": "https://www.bodyhackguide.co/guides/dosage/cagrilintide"
      }
    ]
  }
]
```